Carbidopa (MK-486) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.
Carbidopa inhibits aromatic-L-amino-acid decarboxylase (DDC), an enzyme important in the biosynthesis of L-tryptamine to 5-HT and in the biosynthesis of L-DOPA to Dopamine (DA). Along with carbidopa, other DDC inhibitors are benserazide (Ro-4-4602), difluromethyldopa, and a-methyldopa.
Used in tandem with levodopa (l-dopa, a dopamine precursor converted in the body to dopamine), it increases the plasma half-life of levodopa from 50 minutes to 1 1/2 hours. The combination carries the brand name Sinemet.
More on [ Carbidopa ]

MedlinePlus: Carbidopa and Levodopa - Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations.
Meta Description: [ Levodopa (Systemic) ]
Stalevo (carbidopa, levodopa and entacapone) - Novartis - Official pharmaceutical site for this combination product for the treatment of Parkinson's disease.
Meta Description: [ Learn about Stalevo, a treatment for Parkinson's disease, and find information for patients and caregivers about Parkinson's disease. ]
| strike in teva tech / ש×××ª× ××××¢ ××§ : part 4 | |